Bempikibart Cut Hair Loss Scores 35.3% in Alopecia Areata Trial
Q32 Bio's bempikibart cut SALT hair-loss scores by 35.3 percent at week 36, with 40 percent of severe alopecia areata patients reaching SALT-20 — even after failing JAK inhibitors.
Q32 Bio's bempikibart cut SALT hair-loss scores by 35.3 percent at week 36, with 40 percent of severe alopecia areata patients reaching SALT-20 — even after failing JAK inhibitors.
We use cookies for analytics and site preferences. Choose what to allow. Cookie policy
